Anna Litsiou

Anna Litsiou is an accomplished International Policy & Intelligence Director at AstraZeneca, specializing in China and International markets with 20 years of regulatory affairs experience. Her expertise spans developing regulatory strategies across diverse therapeutic areas including oncology, respiratory, neurodegenerative diseases, and advanced therapy medicinal products. Anna leads AstraZeneca’s International Regulatory Affairs Policy Advocacy Framework, driving initiatives in adaptive regulatory pathways, electronic product information, and real-world evidence. Her career includes strategic regulatory leadership roles at Biogen, Orchard Therapeutics, Shire, Astellas, and GlaxoSmithKline, where she successfully navigated complex global regulatory landscapes across more than 100 international markets. She has spearheaded groundbreaking initiatives like AstraZeneca’s participation in the International ACS Workshare for biologics and accelerated approvals through FDA’s Project Orbis. Anna actively represents industry perspectives through organizations including EFPIA, PhRMA, and IFPMA. She holds a PhD in Developmental Neurobiology from King’s College London, an Executive Global Asia MBA jointly awarded by Columbia Business School, Hong Kong University, and London Business School, and a BSc in Biomedical Sciences from the University of Portsmouth.